Skip to main content
Menu

AAV Production Platform

Vectonize and HEKcellence AAV production platform

How the HEK do I improve vector manufacturability?

Are you struggling to find a scalable suspension-adapted producer line? Wrestling with problematic payloads? Low production yields? Or a high proportion of empty vectors?

At Revvity, we're constantly innovating to solve our customers' greater challenges in our mission to transform human health. Drawing on decades of experience in viral vector manufacturing and expression platforms, we have developed a novel AAV production platform and are now looking for partners like you to put it to the test and see how it adds value to your gene therapy program.

Vectonize transgene suppression technology

Overcome production issues with challenging transgenes which interfere with host cell processes, preventing or reducing production of AAV vectors. Our new proprietary Vectonize™ transgene suppression technology prevents expression of your target sequence during production, improving or even enabling production of interfering protein payloads.

We've seen exciting results from our in-house data:

  • Up to 85-fold yield increases for problematic payloads
  • Up to 4-fold yield increase for other genes expressed
AAV Production Platform
AAV2 variant transfection reagent fig1a
AAV2 variant transfection reagent fig1b

Figure 1) illustrates the impact on yields when challenging transgenes are suppressed during production in suspension adapted HEK293 host line. In this case transgene was Receptor-Interacting Protein Kinase 3 (RIP3), associated with necrotic cell death.

Our Vectonize technology can be easily integrated into existing platforms and processes or used with our HEKcellence expression platform.

If you'd like to learn more, register your interest in our beta program below.

HEKcellence expression platform

Providing the foundation to our AAV production platform is our HEKcellence™ expression system.

  • Suspension-adapted HEK293 cells with full traceability
  • Complete with plasmid kits available for different serotypes and associated protocols
  • Adaptable to different processes
  • Flexible license agreement that's portable to preferred CDMO partners

Our in-house data shows the HEKcellence expression platform can produce higher quality vectors by increasing the proportion with full payloads, providing a route to lower dose requirements and ultimately reduced treatment costs and improved drug safety profiles.

HEK cellence performance figure 2a
HEK cellence graph 2b new

Figure 2a) Compares titre and % full ratio between HEKcellence and leading alternative platform.
2b) illustrates the consistent performance of HEKcellence across different serotypes & with large cargo sizes

Register for our beta program to discover what the HEKcellence platform can do for you.

Join our beta program

We invite you to participate in our beta testing program for the Vectonize and HEKcellence AAV production platform. After registering your interest, our team will contact you to provide more information, outline our commitments to you as a participant and what we expect from you. 

Together, we can improve the manufacturability of gene therapies and help transform human health.

Register your interest

The Vectonize™ technology and HEKcellence™ platform are available for research, clinical, and commercialization applications, including services, under specific limited licenses from Revvity.

HEK293 cells are under license from Advec Inc

You may also be interested in

View all View less
line

Questions?
We're here to help.

Contact us

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.

Revvity AI Assistant Beta